C. Neslusan

The Cost-Effectiveness Of Canagliflozin Verse Liraglutide In Patients With Type 2 Diabetes (T2dm) Failing To Achieve Glycaemic Control On Metformin Monotherapy In Ireland

were sourced from the literature. Both costs and outcomes were discounted at 5%. Results: Incremental costs, QALYs and ICERs for canagliflozin vs. sitagliptin were € 1,360, 0.059 QALYs and € 23,118 per QALY, respectively, in dual therapy; € 108, 0.093 QALYs and € 1,172 per QALY, respectively, in triple therapy; and € 550, 0.068 QALYs and € 8,047 per QALY, respectively, in add-on to insulin. In all three scenarios, canagliflozin was cost-effective using the acceptable willingness-to-pay threshold in Ireland. Sensitivity analyses suggest that these results are robust. ConClusions: These simulations suggest that the use of canagliflozin in patients in need of additional glycaemic control in dual, triple and add-on to insulin lines of therapy is a more efficient use of health care funds than the use of sitagliptin in the Irish setting.

PDB25 THE ECONOMIC IMPACT OF WEIGHT LOSS FOR PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS (T2DM) IN THE US

The analysis is conservative (with most of the cost-offsets related to reductions in the risk of CHF) so the true value of such an intervention is undoubtedly larger. A number of benefits of weight loss were not included, such as reduced insulin resistance and improved HbA1c control, improvements in blood pressure and serum lipid values, as well as reductions in the risk of some important forms of cancer and other obesity-related illnesses. These model results rely on the UKPDS risk equations, currently the best available to examine disease progression in newly diagnosed T2DM. Since these risk equations were formulated using step-wise regression, variables not meeting statistical significance were omitted. As noted by the developers, other explanatory variables in the regressions may have masked the direct effect of weight on outcomes other than CHF. Additionally, the estimate of the effect of a change in weight on CHF is derived from a comparison of individuals with different BMIs and does not come from a comparative intervention trial. Different types of weight loss interventions (e.g., exercise vs. diet) may yield different results. Clinical studies are required to verify that the benefits associated with lower body weight modeled in this application do, in fact, apply when weight is reduced by alternative types of interventions. Future work would also benefit from updated estimates of the QALY associated with weight change as the current estimate is derived from data collected in the late 1990’s. PDB25 THE ECONOMIC IMPACT OF WEIGHT LOSS FOR PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS (T2DM) IN THE US Willis M1, Asseburg C2, Neslusan C3, He J3 and Ingham, M4